Lupin informs about press release

17 Jun 2021 Evaluate

Lupin has informed that it has enclosed is a Press Release on 17th June 2021 as regards receipt of USFDA approval for the Company’s Sevelamer Hydrochloride Tablets, 400 mg and 800 mg to market a generic equivalent of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×